Novo Nordisk Raises 2026 Outlook Amid Strong Obesity Drug Sales but Declines 2027 Guidance
Novo Nordisk (NVO) shares rose approximately 5% following a third-quarter earnings report that exceeded Wall Street expectations. Third-quarter sales reached $11.9 billion, driven largely by a 22% surge in obesity drug sales. Consequently, the company raised its full-year outlook for the second time in three months, narrowing expected sales growth to between a 2% decline and a 2% gain. Despite the positive momentum, CEO Mike Doustdar declined to provide specific guidance for 2027, citing upcoming leadership changes including the departure of CFO Karsten Munk Knudsen. While the company highlighted strengths such as the successful launch of Wegovy pills and expanded Medicare coverage for seniors, it also noted headwinds including patent expirations for semaglutide in international markets like China and a potential plateau in weight-loss drug demand without government assistance.
Topics: earnings report executive change guidance upgrade obesity drugs revenue growth
Read the full article at Motley Fool
Part of the story Loar Holdings Raises 2026 Sales Outlook and Provides Strong 2027 Guidance (7 articles)